Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

26.05.2020 | short review | Ausgabe 3/2020

memo - Magazine of European Medical Oncology 3/2020

Myeloid diseases—Chronic Myeloid Leukemia (CML)—report from ASH 2019 on new developments

memo - Magazine of European Medical Oncology > Ausgabe 3/2020
Prim. Univ.-Prof. Dr. Andreas L. Petzer
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


The recent American Society of Hematology (ASH) annual meeting, held in Orlando, Florida, in December 2019 was an exciting meeting for researchers and clinicians working in the field of chronic myeloid leukemia (CML), as well as for patients suffering from the disease. Interesting updates were presented on new kinase inhibitors (TKI) demonstrating great potential with low toxicities in heavily pretreated patients. Moreover, the 10-year follow-up data of the ENESTnd Study, comparing 2nd generation (2ndG) TKI nilotinib with imatinib showed a continuous benefit of the 2ndG TKI in achieving deeper molecular responses and less progressions to accelerated phase (AP) and blast crisis (BC), but no benefit in progression-free (PFS) or overall survival (OS). Encouraging data were also presented on the treatment of CML BC by combining conventional chemotherapy (FLAG-IDA) with TKI therapy (Ponatinib). Furthermore, great efforts have been undertaken to be able to predict the likelihood of successful TKI cessation in deep molecular remission for individual CML patients in first chronic phase (CP).

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2020

memo - Magazine of European Medical Oncology 3/2020 Zur Ausgabe